Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360 — Valery Fikkert (2004) | RDL Network
Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360
Article 2004 en
Authors
VF
Valery Fikkert
AH
Anneleen Hombrouck
BR
Barbara Van Remoortel
Abstract
1 min read
The accumulation of integrase mutations coincided with an increasing level of (cross-)resistance of IIIB/S-1360(res). Integrase-chimeric virus technology confirmed that the integrase mutations are indeed fully responsible for the resistance phenotype of IIIB/S-1360.
Valery Fikkert, Bénédicte Van Maele, Jo Vercammen, Anke Hantson, Barbara Van Remoortel, Martine Michiels, Cristina Gurnari, Christophe Pannecouque, Marc De Maeyer, Yves Engelborghs, De Clercq Erik, Zeger Debyser, Myriam Witvrouw
Anke Hantson, Valery Fikkert, Barbara Van Remoortel, Christophe Pannecouque, Peter Cherepanov, Barry Matthews, George Holan, De Clercq Erik, Anne‐Mieke Vandamme, Zeger Debyser, Myriam Witvrouw
Discussion(0)
No comments yet. Be the first to comment.